S&P 500 Futures
(-0.04%) 5 306.00 points
Dow J Futures
(0.02%) 40 153 points
Nasdaq Futures
(-0.09%) 18 488 points
Oil
(0.30%) $81.59
Gas
(-1.28%) $1.696
Gold
(0.02%) $2 213.20
Silver
(-0.84%) $24.54
Platinum
(-0.43%) $905.75
USD/EUR
(0.44%) $0.928
USD/NOK
(0.78%) $10.85
USD/GBP
(0.39%) $0.794
USD/RUB
(-0.09%) $92.36

Realtime updates for Bavarian Nordic A/S [BVNRY]

Exchange: OTC Sector: Healthcare Industry: Biotechnology
Last Updated27 Mar 2024 @ 12:10

0.03% $ 7.46

Live Chart Being Loaded With Signals

Commentary (27 Mar 2024 @ 12:10):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...

Stats
Today's Volume 1 338.00
Average Volume 6 090.00
Market Cap 1.74B
EPS $0 ( 2024-03-07 )
Next earnings date ( $0 ) 2024-05-14
Last Dividend $0.593 ( 2020-03-27 )
Next Dividend $0 ( N/A )
P/E 7.93
ATR14 $0 (0.00%)

Bavarian Nordic A/S Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bavarian Nordic A/S Financials

Annual 2023
Revenue: $7.06B
Gross Profit: $4.52B (64.07 %)
EPS: $19.23
Q4 2023
Revenue: $2.45B
Gross Profit: $1.62B (66.00 %)
EPS: $11.75
Q3 2023
Revenue: $1.38B
Gross Profit: $862.03M (62.63 %)
EPS: $-1.470
Q2 2023
Revenue: $1.99B
Gross Profit: $1.30B (65.58 %)
EPS: $2.37

Financial Reports:

No articles found.

Bavarian Nordic A/S Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Bavarian Nordic A/S Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Potential for dividend initiation, but uncertain (13.21%)
Information
First Dividend $0.593 2020-03-27
Last Dividend $0.593 2020-03-27
Next Dividend $0 N/A
Payout Date 2020-04-06
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.593 --
Avg. Dividend % Per Year 0.00% --
Score 2.27 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.34
Div. Directional Score 7.53 --
Next Divdend (Est)
(2024-03-28)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
2.27
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
VDMCY Ex Dividend Knight 2023-06-22 Semi-Annually 0 0.00%
MNESP Ex Dividend Knight 2023-08-15 Quarterly 0 0.00%
CSXXY Ex Dividend Knight 2023-09-15 Semi-Annually 0 0.00%
SLVYY Ex Dividend Knight 2023-05-15 Semi-Annually 0 0.00%
HLLGY Ex Dividend Knight 2023-05-02 Annually 0 0.00%
BDULF Ex Dividend Knight 2023-09-12 Annually 0 0.00%
YAMHF Ex Dividend Junior 2023-12-28 Annually 0 0.00%
NWYF Ex Dividend Junior 2023-08-04 Semi-Annually 0 0.00%
EBGEF Ex Dividend Knight 2023-08-14 Quarterly 0 0.00%
SYIEY Ex Dividend Knight 2023-05-11 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2091.5005.828.74[0 - 0.5]
returnOnAssetsTTM0.1031.2006.577.89[0 - 0.3]
returnOnEquityTTM0.1531.5009.4110.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.9380.8005.314.25[1 - 3]
quickRatioTTM1.3420.8006.815.45[0.8 - 2.5]
cashRatioTTM0.5301.5008.1710.00[0.2 - 2]
debtRatioTTM0.00430-1.5009.93-10.00[0 - 0.6]
interestCoverageTTM25.161.0001.7931.793[3 - 30]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
freeCashFlowPerShareTTM1.8492.009.0810.00[0 - 20]
debtEquityRatioTTM0.00597-1.5009.98-10.00[0 - 2.5]
grossProfitMarginTTM0.6521.0002.472.47[0.2 - 0.8]
operatingProfitMarginTTM0.2151.0007.707.70[0.1 - 0.6]
cashFlowToDebtRatioTTM18.151.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.4920.800-0.0521-0.0416[0.5 - 2]
Total Score10.72

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM2.671.0009.830[1 - 100]
returnOnEquityTTM0.1532.509.6210.00[0.1 - 1.5]
freeCashFlowPerShareTTM1.8492.009.3810.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.002421.500-3.320[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1581.0008.540[0.1 - 0.5]
Total Score4.34

Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators